Metabolic dysfunction-associated steatohepatitis (MASH), a severe form of nonalcoholic fatty liver disease, has become an epidemic, impacting over 115 million people globally. Linked to obesity and cardiovascular diseases, its treatment landscape remains sparse. However, recent developments, including Novo Nordisk's acquisition of Akero Therapeutics and promising clinical trials, suggest a pivotal shift towards therapies targeting metabolic dysfunction as an interconnected system. This evolution highlights the urgent need for effective MASH treatments, improved patient stratification, and comprehensive care pathways.
Newsletters
Receive the latest pharmaceutical news, personalities, education, and career development – weekly to your inbox.